Back to Search
Start Over
Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease
- Source :
- Digestion. 90:130-136
- Publication Year :
- 2014
- Publisher :
- S. Karger AG, 2014.
-
Abstract
- Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.
- Subjects :
- Adult
Male
musculoskeletal diseases
medicine.medical_specialty
Adolescent
medicine.medical_treatment
Anti-Inflammatory Agents
Disease
Antibodies, Monoclonal, Humanized
Young Adult
Crohn Disease
Early Medical Intervention
Internal medicine
Intervention (counseling)
medicine
Adalimumab
Humans
Young adult
skin and connective tissue diseases
Aged
Retrospective Studies
Crohn's disease
Tumor Necrosis Factor-alpha
business.industry
Remission Induction
Gastroenterology
Retrospective cohort study
Bowel resection
Middle Aged
Prognosis
medicine.disease
Surgery
Intestines
Treatment Outcome
Monoclonal
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 14219867 and 00122823
- Volume :
- 90
- Database :
- OpenAIRE
- Journal :
- Digestion
- Accession number :
- edsair.doi.dedup.....d31067712125d53570ca628f5275c506
- Full Text :
- https://doi.org/10.1159/000365783